Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia (REVIVE)
A Multi-Center, Double-Blind, Randomized Placebo-Controlled Investigation of Autologous Muscle Derived Cells (AMDC) for the Treatment of Tongue Dysphagia Resulting From the Treatment of Head and Neck Cancer
Sponsor: California Institute for Regenerative Medicine (CIRM)
Listed as NCT05421689, this PHASE1/PHASE2 trial focuses on Oropharyngeal Dysphagia and remains ongoing. Sponsored by California Institute for Regenerative Medicine (CIRM), it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jan 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Mar 2023 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- California Institute for Regenerative Medicine (CIRM)
- Cook MyoSite
- University of California, Davis
For direct contact, visit the study record on ClinicalTrials.gov .